Conflict of Interest: SAE is an employee and shareholder of GlaxoSmithKline. SMS is an employee of the University of North Carolina Wilmington and a consultant to INC Research LLC, which coordinated the daily operations of the registry. GlaxoSmithKline paid INC Research to oversee the registry, but S.M.S. was not compensated for any activities related to her participation as an author on this manuscript.
Final Results From the 16-Year Sumatriptan, Naratriptan, and Treximet Pregnancy Registry
Article first published online: 7 MAY 2014
© 2014 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 54, Issue 7, pages 1158–1172, July/August 2014
How to Cite
Ephross, S. A. and Sinclair, S. M. (2014), Final Results From the 16-Year Sumatriptan, Naratriptan, and Treximet Pregnancy Registry. Headache: The Journal of Head and Face Pain, 54: 1158–1172. doi: 10.1111/head.12375
Financial Support: GlaxoSmithKline funded this registry (Study 112914).
Clinical Trial Registration: ClinicalTrials.gov. NCT01059604
- Issue published online: 16 JUL 2014
- Article first published online: 7 MAY 2014
- Manuscript Accepted: 25 MAR 2014
- GlaxoSmithKline. Grant Number: 112914
Appendix S1.—Data Collection Forms
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.